This webinar will discuss ongoing work to apply T-cell receptor sequencing (TCRseq) approaches to immunotherapy monitoring for melanoma patients.
Despite its undisputed superior clinical efficacy compared to chemo- or radiotherapy, anti-PD-1 monotherapy remains inefficient on more than 60 percent of cancer patients. Acute toxicities are less common than those reported for anti-CTLA-4 therapy but remain an appreciable risk for patients. For these reasons, defining early and robust predictive markers of clinical response is crucial both to improve patient management and to reduce treatment costs. Furthermore, the comprehensive analysis of PD-1 regulation and signaling will also have a considerable impact on the optimization of other immunotherapies such as T-cell-based immunotherapies.
In this webinar, researchers from the Inserm Cancer Research Center in Nantes, France, will share findings from studies seeking to understand the molecular mechanisms regulating PD-1 expression in melanoma-specific T lymphocytes. Their work points toward methods for monitoring the immune responses of cancer patients treated with anti-PD-1 antibodies as well as for the selection of optimal effector T cells for adoptive cell transfer treatments.
The presentations will offer new prospects for patient monitoring based on TCRseq approaches.